Protein kinase D (PKD) regulates the fission of vesicles originating from the trans-Golgi network 1,2 . We show that phosphatidylinositol 4-kinase IIIβ (PI4KIIIβ) -a key player in the structure and function of the Golgi complex 3 -is a physiological substrate of PKD. Of the three PKD isoforms, only PKD1 and PKD2 phosphorylated PI4KIIIβ at a motif that is highly conserved from yeast to humans. PKD-mediated phosphorylation stimulated lipid kinase activity of PI4KIIIβ and enhanced vesicular stomatitis virus G-protein transport to the plasma membrane. The identification of PI4KIIIβ as one of the PKD substrates should help to reveal the molecular events that enable transport-carrier formation.
PI4KIIIβ
3 , of which PI4KIIα 14 and PI4KIIIβ 16 have been implicated in Golgi-complex-to-cell-surface transport based on findings from knockdown by small interfering RNA and overexpression of a kinase-dead mutant, respectively. We tested for a potential connection between PKD and PI4Ks in Golgi-complex-to-cell-surface transport. Anti-PI4KIIIβ antibodies stain perinuclear reticular structures that are also stained by antibodies directed against trans-Golgi-membrane-associated proteins (Fig. 1a) . When expressed as a Flag-tagged protein, PI4KIIIβ also localized to the Golgi complex (Fig. 1b) . We visualized the intracellular distribution of Flag-PI4KIIIβ and PKD with green fluorescent protein (GFP)-tagged wild-type PKD1, PKD2 or PKD3 proteins (Fig. 1c) . All three PKD-GFP wild-type isoforms colocalized with Flag-tagged PI4KIIIβ at the Golgi complex. Overexpression of the kinase-dead mutant of PKD1-GFP revealed partial segregation from Flag-PI4KIIIβ, with PKD1-KD-GFP being detectable in extended post-TGN tubular structures and vesicles, which is a morphological phenotype of PKD dysfunction at the TGN 1, 10 . By contrast, Flag-PI4KIIIβ remained exclusively localized at the Golgi complex, and co-staining with PKD1-KD-GFP at vesicles and tubules was not detectable in these cells (Fig. 1d) . Using in vitro kinase assays, we examined whether Flag-PI4KIIIβ is a substrate for any of the three PKD isoforms. HEK293 cells were cotransfected with cDNAs encoding Flag-PI4KIIIβ and PKD1-GFP, PKD2-GFP and Flag-tagged PKD3, respectively. Flag-PI4KIIIβ and PKD1-GFP, PKD2-GFP or PKD3-Flag were immunoprecipitated using Flag-and GFP-specific antibodies, respectively, and were subjected to in vitro kinase assays using [γ-32 P]-ATP (Fig. 2a) . All three PKD isoforms phosphorylated Flag-PI4KIIIβ, with PKD1 being the strongest and PKD3 being the weakest compared with the level of PKD autophosphorylation. Lack of Flag-PI4KIIIβ phosphorylation in the presence of a kinase-dead mutant, PKD1-KD-GFP, indicates that phosphorylation is directly mediated by PKD (Fig. 2a) . We did not detect a direct interaction between PKD and Flag-PI4KIIIβ by co-immunoprecipitation in cells co-expressing the two proteins. However, this interaction may be transient and stimulated by signals that promote trafficking, which were L E T T E R S not reconstituted under our experimental conditions. Is Flag-PI4KIIIβ also phosphorylated by PKD in intact cells? To address this question, we used an antibody that specifically recognizes a phosphorylated PKD consensus motif (anti-PKD pMOTIF 17 ). PKD preferentially phosphorylates serines or threonines with a leucine or isoleucine in the -5 position and an arginine in the -3 position 18, 19 . PKD contains this motif and we used PKD autophosphorylation to control the specificity and functionality of this antibody. In HEK293 cells, PKD-GFP fusion protein migrates in a SDS-PAGE as a double band, representing differentially phosphorylated PKD species. By contrast, the kinase-dead PKD isoforms, due to lack of autophosphorylation, appear as a single protein band 10 . The PKD pMOTIF antibody recognizes all three wild-type PKDs, but not their respective kinase-dead mutants, demonstrating the antibody specificity for PKD phosphorylation motifs (Fig. 2b) . The antibody also recognizes this PKD pMOTIF in PI4KIIIβ, which is ectopically expressed in HEK293 cells (Fig. 2c) . PKD1-KD is dominant-negative for the endogenous, wild-type PKD function 2, 20 . In vivo phosphorylation of PI4KIIIβ by PKD should, therefore, be inhibited by overexpression of the dominant-negative PKD variant. We transiently expressed wild-type PKD1, PKD1-∆PH (a variant lacking the negative regulatory pleckstrin homology (PH) domain and displaying enhanced enzymatic activity 10 ) or PKD1-KD. We then cultured the cells for 24 h and subsequently transfected the cells with Flag-PI4KIIIβ, followed by an additional 24 h incubation period. PKD-GFP and Flag-PI4KIIIβ expression and phosphorylation levels were analysed by western blotting the total cell lysates. Overexpression of PKD1-KD-GFP fusion protein reduced the recognition of Flag-PI4KIIIβ with the PKD pMOTIF-specific antibody, whereas expression of wild-type PKD1-GFP or PKD1-∆PH-GFP markedly increased its detection compared with the vector control (Fig. 2d) . This finding provides strong evidence that PI4KIIIβ is a physiological substrate of PKD. Notably, the pMOTIF antibody does not detect PKD1-∆PH, which is in accordance with the localization of the recognized phosphorylation site within the PH domain (P. Storz, unpublished observations). Fig. 3a is a schematic depiction of the eight known phosphorylation sites in PI4KIIIβ 21 . Alignment with the PKD consensus motif in Kidins220 or HPK1, which are known PKD substrates 22, 23 , revealed that two of these phosphorylation residues (Ser 294 and Ser 496) match the potential PKD consensus sequence. Ser 294 is present in the common region between PI4KIIIβ and its yeast homologue Pik1p, and is highly conserved from yeast to humans. Both serines were replaced with alanine and expressed in HEK293 cells as Flag-PI4KIIIβ S294A and Flag-PI4KIIIβ S496A , respectively. Only the S294A mutation abolished the detection of Flag-PI4KIIIβ by the PKD pMOTIF antibody (Fig. 3b) . Moreover, this mutation strongly reduced the ability of PKD1-GFP and PKD2-GFP fusion proteins to phosphorylate Flag-PI4KIIIβ in an in vitro kinase assay (Fig. 3c) . Interestingly, in vitro phosphorylation of (Fig. 3d) . Co-transfection of a PKD mutant that is not targeted by the RNAi vectors rescues phosphorylation of Flag-PI4KIIIβ and confirms the specificity of the PKD-mediated phosphorylation ( Fig. 3e ; also, see Supplementary Information, Fig. S1 ). Interestingly, knock-down of one of the two PI4KIIIβ-phosphorylating PKD isoforms was sufficient in inhibiting Ser 294 phosphorylation. With the readily detectable levels of endogeneous PKD, this indicates an at least partially non-redundant function of PKD1 and PKD2, and indicates that the two isoforms may target distinct pools of PI4KIIIβ at the TGN. In support of this reasoning is the recent proposal that PI(4)P is located in functionally distinct TGN domains that can be discriminated by their specific lipid and protein content 16 . PKD1 and PKD2 could be recruited to these separate domains at the TGN, where different cargo is sorted into distinct carriers. The latter is in accordance with the proposal that PKD isoforms serve nonredundant functions in the transport of distinct cargo proteins 2 .
L E T T E R S
To further investigate phosphorylation of PI4KIIIβ at Ser 294 in intact cells, we developed a phospho-specific antibody against the peptide epitope surrounding this residue in PI4KIIIβ. Transfected wild-type Flag-PI4KIIIβ was detected with the pS294 phospho-antibody, but not Flag-PI4KIIIβ S294A (Fig. 3f) . The phospho-antibody pS294 also detects immunprecipitated, endogenously phosphorylated PI4KIIIβ. Similarly, endogenous p-PI4KIIIβ can be precipitated with this antibody, although it is precipitated less efficiently compared with a polyclonal immune serum developed against different epitopes (Fig. 3f) . What is the functional consequence of Ser 294 phosphorylation of PI4KIIIβ by PKD1 and PKD2? To address this question, we first investigated the localization of the mutated lipid kinase in COS7 cells. The S294A-mutated Flag-PI4KIIIβ also localized to the Golgi compartment in a similar way to its wild-type counterpart (Fig. 4a) . Notably, neither overexpression of PI4KIIIβ nor PI4KIIIβ S294A caused apparent changes in the distribution of mannose-6-phosphate receptor (data not shown). To investigate whether the phosphorylation of Ser 294 in PI4KIIIβ is relevant for its activity, we performed lipid-kinase assays. HEK293 cells transfected with Flag-tagged PI4KIIIβ constructs were used. Flag-PI4KIIIβ proteins were precipitated with anti-Flag M2 antibodies and analysed for lipid-kinase activity using [γ- S294A was 60% less than its wild-type counterpart (Fig. 4b, left panel) . To further analyse the functional consequences of PKD-mediated phosphorylation on lipid-kinase
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activity, we investigated the effect of overexpression of PKD1-GFP variants on Flag-PI4KIIIβ wild-type lipid-kinase activity. As expected from basal kinase activity of endogeneously expressed PKD 10 , phosphorylated species of PI4KIIIβ and lipid-kinase activity were readily deteced in the vector control (Fig. 4b, right panel) . Both PI4KIIIβ phosphorylation and lipidkinase activity were further enhanced following expression of PKD1-∆PH (Fig. 4b, right panel) . By contrast, overexpression of PKD1-KD decreased PI4KIIIβ phosphorylation and lipid kinase activity below vector control (Fig. 4b, right panel) , in accordance with the known dominant-negative action of kinase-inactive PKD mutants. These data, together with those shown in Fig. 2d , provide compelling evidence that PKD phosphorylation of PI4KIIIβ at Ser 294 regulates lipid-kinase activity.
It has been reported that kinase-dead PI4KIIIβ D656A partially blocked the transport of vesicular stomatitis virus G-protein (VSVG)-GFP protein to the plasma membrane 16 . Similarly, through dominant-negative action, PKD1-KD and PKD2-KD inhibit the transport of basolateral cargo from the TGN to the plasma membrane 2 . Our findings reveal that PKD1 and PKD2 regulate the lipid-kinase activity of PI4KIIIβ by phosphorylation. But is there a functional link between the phosphorylation of PI4KIIIβ by PKD and Golgi-to-cell-surface transport? We compared the effect of overexpression of PI4KIIIβ and of PI4KIIIβ 
cellular VSVG-GFP protein.
As expected, the expression of PKD1-KD significantly reduced the transport of VSVG-GFP protein to the plasma membrane (Fig. 4c, upper panel) . Expression of wild-type Flag-PI4KIIIβ led to an increase in TGN-to-plasma-membrane export of VSVG-GFP (145% of vector control), whereas the phosphorylation-site-deficient mutant, PI4KIIIβ
S294A
, did not affect basal VSVG-GFP transport. This indicates that, unlike PKD1-KD, the PI4KIIIβ S294A mutant does not act in a dominant-negative manner. In support of this, the expression of kinase-dead Flag-PI4KIIα K152A alone or together with the phosphorylation-site-deficient mutant, Flag-PI4KIIIβ S294A , also did not inhibit secretory transport of VSVG-GFP (see Supplementary Information,  Fig. S2 ). This is not surprising as mammalian cells contain at least three Golgi-complex-localized PI4Ks and all three PI4Ks have to be depleted to significantly reduce PI(4)P levels at the Golgi complex 24 . The lack of dominant-negative action of overexpressed lipid-kinase mutants has already been reported. In yeast, Pik1p function is highly allele specific 12 .
In mammalian cells, a catalytically inactive variant of PI4KIIα is not dominant-negative 14 . Moreover, PKD1-KD is likely to have additional substrates that are involved in vesicle trafficking from the Golgi complex. Malhotra and co-workers have recently proposed a model in which 
L E T T E R S
DAG kinase is suggested to be a PKD target 9 . In summary, PI4KIIIβ is involved in Golgi-to-cell-surface transport. PI4KIIIβ is phosphorylated at Ser 294 by PKD1 and PKD2, but not PKD3. This phosphorylation increases the lipid-kinase activity of the PI4KIIIβ. We propose that PKD acts as a 'bottleneck' at the TGN, regulating secretory transport processes by phosphorylating a set of proteins involved in the generation and/or fission of transport vesicles. PI4KIIIβ is one of the PKD substrates at the Golgi apparatus. Our findings reveal that trafficking from the TGN requires the combined action of a protein and a lipid kinase. How these two kinases promote membrane fission during vesicle formation is the obvious next challenge.
METHODS
Antibodies and reagents. Anti-PI4KIIIβ antibodies were purchased from Becton Dickinson (Heidelberg, Germany) and Upstate Biotechnology (Waltham, MA). Alexa488-or Alexa546-labelled anti-mouse or anti-rabbit IgG for immunofluorescence microscopy were obtained from Molecular Probes (Eugene, OR). The anti-GFP antibody was obtained from Roche (Mannheim, Germany), the anti-Flag M2 and the anti-actin antibodies from Sigma-Aldrich (Deisenhofen, Germany), the anti-HA antibody from NEB (Beverly, MA), the monoclonal anti-tubulin antibody was from Neomarkers (Fremont, CA) and the anti-p230 monoclonal antibody was from Becton Dickinson. The antibody anti-PKD C-20 recognizing the carboxy-terminal domain in PKD1 and PKD2 was from Santa Cruz (Santa Cruz, CA). The anti-PKD3 antibody was a gift from Sharon Matthews and Andrew Scharenberg (University of Washington, Seattle, USA). The monoclonal antibody I1 (8G5F11) recognizing the extracellular domain of VSVG was kindly provided by Doug Lyles (Wake Forest University School of Medicine, North Carolina, USA). The anti-PKD pMOTIF antibody was generated as described in detail previously 17 . The polyclonal anti-pS294 antibody was generated by immunizing rabbits with the peptide NH 2 -CLKRTApSNPL-CONH 2 (amino acids 289-297 in human PI4KIIIβ).
DNA constructs. Flag-tagged PI4KIIIβ was generated by amplification of fulllength human PI4KIIIβ from HEK293 cDNA by polymerase chain reaction (PCR), using a 5′ sense primer containing an EcoRV site and a 3′ antisense primer containing an XhoI site. The fragment was cloned into EcoRV-and XhoI-digested pCR3V62-Met-Flag (kindly provided by J. Tschopp, University of Lausanne, Switzerland) to generate pCR3V62-Met-Flag-PI4KIIIβ. The point mutations in Flag-PI4KIIIβ were generated from this construct by site-directed mutagenesis (Stratagene, La Jolla, CA) following the manufacturers instructions. The following oligonucleotides were used: Flag-PI4KIIIβ D656A : 5′-CTGCAAGCAAGGCC AGACACAATGGG-3′ and 5′-CCCATTGTGTCTGGCCTTGACTTGCAG-3′; Flag-PI4KIIIβ S294A : 5′-AAACGAACAGCCGCCAACCCTAAAGTG-3′ and 5′-CACTTTAGGGTTGGCGGCTGTTCGTTT-3′; Flag-PI4KIIIβ S496A : 5′-CGCC GGCGCCTTGCGGAACAGCTGGCT-3′ and 5′-AGCCAGCTGTTCCGCAA GGCGCCGGCG-3′. The plasmids pEGFP-N1-PKD1, pEGFP-N1-PKD1 ∆PH and pEGFP-N1-PKD1 K612W (PKD1-KD) were described previously 10 . The plasmids pEGFP-N1-PKD2, pEGFP-N1-PKD3 and pCR3V62-PKD3-Flag were generated by amplification of full-length human PKD2 and PKD3 from HEK293 cDNA by PCR, using a 5′ sense primer containing an EcoRI site (PKD2) or a SacI site (PKD3) and a 3′ antisense primer containing a BamHI site (PKD2) or a XmaI site (PKD3). Mutations at Lys 580 (PKD2) and Lys 605 (PKD3) to generate kinase-dead versions of PKD2 and PKD3 were introduced, as described for PKD1-KD. The integrity of all constructs was verified by DNA sequencing. To silence the expression of PKD1 and PKD2, pSuper-PKD1-RNAi vectors (Seq. 1) and pSuper-PKD2-RNAi were used as described previously 25 . PKD1-RNAi Seq. 2 was as follows: 5′-GATCCCCGTTCCCTGAATGTGGTTTCTTCAAG AGAGAAACCACATTCAGGGAACTTTTTGGAAA-3′ and 5′-AGCTTTTC CAAAAAGTTCCCTGAATGTGGTTTCTCTCTTGAAGAAACCACATTCA GGGAACGGG-3′. PKD3-RNAi was: 5′-GATCCCCGTCCTAAGACGGGAC TCTCTTCAAGAGAGAGAGTCCCGTCTTAGGACTTTTTGGAAA-3′ and 5′-AGCTTTTCCAAAAAGTCCTAAGACGGGACTCTCTCTCTTGAAGAG AGTCCCGTCTTAGGACGGG-3′. The RNAi sequences for PKD1-RNAi (Seq. 1) and PKD2-RNAi have been described before 25 . The PKD1 mutant with silent mutations in the RNAi-targeted sequence has also been described before 26 . The temperature-sensitive folding mutant of the VSV G-protein, VSVG-ts045-GFP, in a pEGFP-N1 vector (Clontech, Heidelberg, Germany) was kindly provided by Kai Simons (MPI Dresden, Germany). The pEYFP-Golgi plasmid contains the sequence for the N-terminal 81 amino acids of the human β1, 4-galactosyltransferase fused to the N terminus of EYFP (Clontech).
Cell culture and transfection. HEK293 and COS7 cells were grown in RPMI, supplemented with 5% or 10% foetal calf serum, respectively, in a humidified atmosphere containing 5% CO 2 . For immunofluorescence, COS7 cells were grown on glass coverslips for 24 h and transfected with lipofectamine 2000 reagent (Invitrogen, Karlsruhe, Germany) according to the manufacturers instructions. HEK293 cells grown in Petri dishes were transfected using TransIT293 reagent (Mirus, Madison, WI).
Immunofluorescence microscopy. Transfected COS7 cells were grown on coverslips, washed with phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde at room temperature for 20 min, and then washed, blocked and permeabilized with blocking buffer (5% normal goat serum and 0.05% Tween 20 in PBS) for 30 min. The coverslips were incubated with the primary antibodies diluted in blocking buffer (1:300) for 2 h, washed, incubated with secondary antibodies diluted in blocking buffer for 1 h, and then washed, mounted in Fluormount G (Southern Biotechnology, Birmingham, AL) and analysed using a confocal laser scanning microscope (TCS SP2; Leica, Bensheim, Germany) using both 488 nm and 568 nm excitation and a ×100 HL Apo objective. Images were processed using Adobe Photoshop. 32 P]-ATP and terminated after 10 min by the addition of 25 µl 5 M HCL. Lipids were extracted by adding 160 µl chloroform/methanol, followed by vigorous mixing and high-speed centrifugation. The bottom phase that contained the lipids was transferred to a new tube, then 20 µl at a time were spotted onto a potassium-oxalate-coated thin-layer chromatography (TLC) plate, and lipids were separated using 0.7 M acetic acid in N-propanol as solvent. TLC was exposed to phosphoimager (Amersham Biosciences, Freiburg, Germany) overnight. The density of spots representing PI(4)P was quantified using ImageQuant software (Amersham Biosciences).
VSVG-GFP transport assay. HEK293 cells grown in
Immunoprecipitation and western blotting. HEK293 cells were harvested, lysed in lysis buffer (20 mM Tris (pH 7.4), 150 mM NaCl, 5 mM MgCl 2 , 1% Triton X-100, plus protease and phosphatase inhibitors), and the proteins were precipitated using anti-GFP antibodies, anti-Flag M2 antibodies or anti-PI4Kβ antibodies.
